Editor’s Notice: The story has been up to date to interchange the faulty content material revealed earlier.Tuesday, Emergent BioSolutions Inc. EBS obtained greater than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at america Division of Well being and Human Providers to ship thousands and thousands of doses of 4 medical countermeasures.These contract modifications will assist guarantee continued provide/stockpiling of crucial medical countermeasures to handle organic threats and emergencies in opposition to anthrax, smallpox, and botulism.The 4 awards embody:
A contract modification valued at $30.0 million to produce Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) this 12 months.
Beforehand generally known as AV7909, Cyfendus is a two-dose anthrax vaccine for post-exposure prophylaxis use in people 18 and older. This new procurement funding is from Emergent’s present 10-year contract with the Biomedical Superior Analysis and Growth Authority.
A contract modification valued at $99.9 million to produce ACAM2000 (Smallpox (Vaccinia) Vaccine, Dwell) this 12 months. That is beneath Emergent’s present 10-year contract with ASPR.
Two new contract choices totaling $122.9 million have been awarded to produce the Strategic Nationwide Stockpile with VIGIV [Vaccinia Immune Globulin Intravenous (Human)] drug product and BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] drug substance and supply of drug manufacturing this 12 months and into early 2025.
VIGIV is used for problems to smallpox vaccination, whereas BAT is indicated for symptomatic botulism following documented or suspected publicity to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric sufferers.
Each are beneath Emergent’s present 10-year contracts with ASPR.
Learn Subsequent:Worth Motion: EBS shares are up 13.6% at $8.02 eventually test Tuesday.Picture by way of UnsplashMarket Information and Knowledge dropped at you by Benzinga APIs© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.